# Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

> **NCT04456439** · — · NO_LONGER_AVAILABLE · sponsor: **Mesoblast International Sàrl**

## Conditions studied

- Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

## Interventions

- **BIOLOGICAL:** Remestemcel-L
- **DRUG:** Hydrocortisone
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT04456439
- **Lead sponsor:** Mesoblast International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456439, "Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT04456439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*